In vitro activity of cefiderocol against Burkholderia cepacia complex and Burkholderia gladioli clinical isolates from cystic fibrosis patients in the United States
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkag347 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Maria F Mojica und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, OH, USA. Hauptthemen laut MEDLINE: Burkholderia cepacia complex, Cystic Fibrosis, Burkholderia gladioli, Anti-Bacterial Agents. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Shionogi Inc., Cleveland Department of Veterans Affairs, Cystic Fibrosis Foundation.
Abstract (Originalsprache)
Background
Burkholderia cepacia complex (Bcc) and Burkholderia gladioli are intrinsically multidrug-resistant pathogens that cause chronic pulmonary infections in individuals with cystic fibrosis (CF) and severe infections in other vulnerable populations. Therapeutic options remain limited as resistance to commonly used agents continues to emerge.
Objectives
To evaluate the in vitro activity of cefiderocol against a collection of Bcc and B. gladioli isolates from individuals with CF in the USA and to compare these findings with historical susceptibility data for 16 other antimicrobial agents.
Methods
A total of 150 clinical isolates representing multiple Bcc species and B. gladioli were tested. Cefiderocol MICs were determined using iron-depleted broth microdilution (ID-BMD) and iron-depleted agar dilution (ID-AD). Species-specific MIC distributions were assessed, and cefiderocol activity was compared with historical MIC data for 16 other antimicrobial agents previously tested against the same isolate panel. Mechanistic studies evaluated blaPenA expression and hydrolysis of cefiderocol by purified PenA1.
Results
Cefiderocol MIC50 and MIC90 values were 0.06 and 8 mg/L, and 0.03 and 8 mg/L, respectively, by both ID-BMD and ID-AD. Low MIC90 values were observed for Burkholderia cenocepacia, B. cepacia, B. gladioli, and most ‘other Bcc’ species, whereas elevated MIC90 values were detected for Burkholderia multivorans and Burkholderia vietnamiensis. Cefiderocol demonstrated the lowest MIC50 values when compared with historical data for 16 other agents; did not induce blaPen expression; and was not hydrolysed by purified PenA1.
Conclusions
Cefiderocol demonstrated broad in vitro activity against Bcc and B. gladioli isolates from individuals with CF and showed stability against key β-lactamase-mediated resistance mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, OH, USA.
- Research Service, VA Northeast Healthcare System, Cleveland, OH, USA.
- CASE-VA Center for Antimicrobial Resistance and Epidemiology, Cleveland, OH, USA.
- Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI, USA.
- Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
- Department of Biochemistry, Case Western Reserve University, Cleveland, OH, USA.
ORCID-Profile: Maria F Mojica, Lindsay J Caverly, Robert A Bonomo, Krisztina M Papp-Wallace
Förderung
- Shionogi Inc.
- Cleveland Department of Veterans Affairs
- Cystic Fibrosis Foundation
- Burkholderia cepacia Laboratory and Repository
- Geriatric Research Education and Clinical Center
- VISN 10
- BLRD VA
- University of Michigan
Zitieren
APA
Mojica, M. F., Zeiser, E. T., Becka, S. A., Caverly, L. J., Lipuma, J. J., Bonomo, R. A., & Papp-Wallace, K. M. (2026). In vitro activity of cefiderocol against Burkholderia cepacia complex and Burkholderia gladioli clinical isolates from cystic fibrosis patients in the United States. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag347
Vancouver
Mojica MF, Zeiser ET, Becka SA, Caverly LJ, Lipuma JJ, Bonomo RA, et al. In vitro activity of cefiderocol against Burkholderia cepacia complex and Burkholderia gladioli clinical isolates from cystic fibrosis patients in the United States. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag347
BibTeX
@article{Mojica2026,
author = {Mojica, Maria F and Zeiser, Elise T and Becka, Scott A and Caverly, Lindsay J and Lipuma, John J and Bonomo, Robert A and Papp-Wallace, Krisztina M},
title = {In vitro activity of cefiderocol against Burkholderia cepacia complex and Burkholderia gladioli clinical isolates from cystic fibrosis patients in the United States},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkag347}
}
EUVIMED